ETNB News

A biotech and a micro-cap ridesharing rental provider entered the public market this past week, and seven companies submitted initial filings. After delaying its offering in the previous week, 89bio (ETNB) priced its upsized $85 million IPO at the midpoint and popped 30% on its first day, the second highest of the 4Q19 so far, before finishing the week up 69%...read more

89bio, a Phase 1 biotech developing therapies for NASH and other metabolic diseases, raised $85 million by offering 5.3 million shares at $16, within the range of $15 to $17, to command a market value of $225 million. The company originally planned to raise $70 million by offering 4.4 million shares at the same range. 89bio plans to list on the Nasdaq under the symbol ETNB. BofA...read more

After a busy week in the IPO market, just one biotech is scheduled to go public in the week ahead. NASH biotech 89bio (ETNB) plans to raise $85 million at a $225 million market cap. The company’s target indication represents a multi-billion-dollar market with no FDA-approved therapy; consequently, there are ...read more

Backed by OrbiMed and Longitude, Phase 1 biotech 89bio (ETNB) is expected to raise $70 million tonight in the fifth NASH-focused biotech IPO of 2019; insiders have indicated on $40 million (57% of the deal). Another NASH biotech, Cirius Therapeutics (CSTX), is in the IPO pipeline, but before this year, the last biotech IPO targeting NASH came in...read more